Publication | Closed Access

Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy

Metabolic SyndromeDrug InteractionsThrombosisLipid DisorderCardiovascular DiseaseAdverse Drug ReactionPharmacologyHyperlipidemiaAmbulatory PatientsPharmacotherapyMedicineAtherosclerosisDyslipidemiaPharmacoepidemiology